(Nasdaq: MDCX) Tops Today's Watchlist Behind 5 Key Potential Catalysts (Strong Analyst Targets)

As innovation meets necessity

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on behalf of Medicus Pharma Ltd. (Nasdaq: MDCX) Tops Today's Watchlist Behind 5 Key Potential Catalysts (Strong Analyst Targets)  *Click Here To Get Our Alerts Faster Via SMS* April 15th Greetings Readers, As innovation meets necessity, a new force in biotechnology is reimagining the future of dermatologic oncology. With the global skin cancer treatment market valued at $10.87Bn in 2024 and expected to reach $19.27Bn by 2032, growing at a 7.42% CAGR, momentum is clear. Amid this rapid expansion, a focused team is pushing forward a breakthrough therapy poised to transform patient care and recovery. Their science is ambitious, their impact promising, and the medical world is taking notice. And with a float of fewer than 9Mn and multiple analyst targets suggesting potentially massive upside, this Nasdaq profile has just overtaken my watchlist once again: *Medicus Pharma Ltd. (Nasdaq: MDCX)* Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents. And based on several potential catalysts, (Nasdaq: MDCX) has pushed its way to the top of my watchlist. Take a look: No. 1 - A Low Float Could Create The Environment For Heightened Volatility. No. 2 - A Visibility Boost Is Incoming As MDCX Signs Strategic Media Agreement. No. 3 - An Average Of 6 Analyst Targets Suggest Major Potential Upside (Quadruple-Digit). No. 4 - The Company Reported Positive Topline Data On A Key Phase 2 Study. No. 5 - Multiple Technical Indicators Point To This Profile Trending Around Oversold Levels. But more on those in a second... Company Breakdown - Medicus Pharma Ltd. (Nasdaq: MDCX) Medicus Pharma Ltd. specializes in rapidly moving forward the clinical development of cutting-edge therapeutic solutions within the biotech and life sciences sector. About SkinJect - Medicus Pharma's (Nasdaq: MDCX) Wholly Owned Subsidiary A novel non-invasive regimen to treat skin cancer; especially Basal Cell Carcinoma. SkinJect Inc. is a development stage biotechnology company focused on developing a novel, localized immunogenic precision therapy for non-melanoma skin cancer, especially basal cell carcinoma (BCC), using a patented dissolvable doxorubicincontaining microneedle array (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. By merging the accuracy of precision drug delivery with the biological impact of immunogenic tumor cell death, SkinJect sits at the intersection of localized chemotherapy and immuno-oncology. It is the kind of quiet but transformational innovation the biotech sector rarely recognizes early — addressing the world’s most common cancer with a first in class non-invasive, next generation localized precision treatment without systemic burden, that could replace surgery in millions of cases globally. BCC is the most common cancer in humans, with over 5 million cases diagnosed in the U.S. each year and perhaps over 30 million worldwide. Surgery is the standard treatment for most BCC patients. Efficacy rates tied to surgery are high, but there is a substantial unmet need for a non-surgical option that offers strong efficacy and is also cost and time efficient. Medicus’ aim is to fulfill this unmet need and potentially create a market opp. in the United States in excess of $2Bn annually. About Recent Acquisition: Antev Ltd. Antev Ltd. is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for high Cardiovascular risk advanced prostate cancer patients and patients with first acute urinary retention (AUR) episodes due to enlarged prostate, collectively representing ~$6Bn in potential market opp.  Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. What sets Teverelix apart is the potential for: Rapid onset of testosterone suppression and prostate shrinkage Avoidance of testosterone flare versus agonists A longer-acting injection schedule (possibly every 6 weeks) Potential for subcutaneous and intra-muscular delivery without daily dosing (vs. Relugolix’s daily oral use) Due to superior formulation, ISRs potentially significantly milder compared to Degarelix ~ 400 pts already included in studies to date & multiple peer reviewed publications Grab Key Sources: MDCX Presentation. MDCX Website. ----- And as I mentioned previously, (Nasdaq: MDCX) has several potential catalysts that could generate breakout buzz. Check them out: No. 1 MDCX Potential Catalyst - A Low Float Could Create The Environment For Heightened Volatility. According to info from the Finviz website, MDCX has a fairly low float. The website reports this profile to have roughly 8.37Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If the company provides positive news towards the first part of 2026, could it help provide a breakout spark when paired with this volatility potential? ----- No. 2 MDCX Potential Catalyst - A Visibility Boost Is Incoming As MDCX Signs Strategic Media Agreement. New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms NEW YORK CITY, NY / ACCESS Newswire / April 7, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX), a precision-guided biotech and life sciences company advancing innovative therapeutic platforms, has entered into a 12-part, one-year strategic media agreement with New to The Street to expand its national and international visibility across television, digital, and outdoor platforms. The campaign will highlight Medicus Pharma's differentiated pipeline, including SkinJect™, a localized immuno-oncology platform targeting non-melanoma skin cancers such as basal cell carcinoma and rare conditions like Gorlin Syndrome, representing a multi-Bn-dollar market opp. The series will also feature Teverelix®, a next-generation GnRH antagonist designed for patients with advanced prostate cancer and acute urinary retention associated with enlarged prostate conditions-addressing a significant and growing global market. ... "Our platform is built to provide public companies with consistent, high-impact visibility across television, digital, and outdoor media," said Vince Caruso, Co-Founder of New to The Street. "Medicus Pharma's innovative therapeutic platforms, particularly SkinJect™ and Teverelix®, represent meaningful advancements in high-demand clinical areas, and we are excited to support their continued growth and in-vest-or awareness." As part of the integrated campaign, Medicus Pharma will benefit from extensive commercial and digital exposure, including 80 monthly television commercial placements in the New York market during peak trading hours, as well as national ad distribution across Bloomberg Television and FOX Business Network. The agreement also includes premium outdoor advertising in New York City, featuring high-frequency digital billboard placements across iconic 42nd Street displays and Times Square, ensuring consistent brand visibility in one of the world's most recognized financial and media corridors. Digital amplification will extend across New to The Street's media ecosystem, including its flagship YouTube channel with over 4.45Mn subscribers and its NewsOut platform, bringing the combined subscriber reach to more than 5.1Mn. The campaign will also include 24 press releases over the course of the year, coordinated social media distribution, and inclusion in targeted ... email newsletters. ... Read the full article here. ----- No. 3 MDCX Potential Catalyst - An Average Of 6 Analyst Targets Suggest Major Potential Upside (Quadruple-Digit). Check out what MarketBeat is reporting: As of Tuesday's close, MDCX had 6 analyst targets pointing to a significant amount of upside potential. In fact, with an average target of $23.50, MDCX could have over 5,000% potential upside from its closing valuation on Tuesday the 17th. MarketBeat reports further that Jason Kolbert of D. Boral Capital has given MDCX a $27 target representing a potential upside over 6,000% from Tuesday's close. Additionally, the website shares Jason McCarthy of Maxim Group has provided a $20 target suggesting 4,500+% potential upside from Tuesday's close. Could (Nasdaq: MDCX) be undervalued from current chart levels? ----- No. 4 MDCX Potential Catalyst - The Company Reported Positive Topline Data On A Key Phase 2 Study. Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDA PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce topline results from its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The Company believes the topline results are not only positive but decision-grade that should support an end of phase 2 (EOP2) meeting with the FDA in the first half of 2026 as well as accelerate partnering readiness. ... “We are extremely encouraged by these topline results, which not only validate management’s scientific and in-vest-ment thesis, but also provide what we consider to be decision-grade evidence of clinical activity, particularly at the 200-microgram dose level,” said Dr. Raza Bokhari, Executive Chairman & CEO of Medicus. “The observed increase in clearance rates at Day 57 in the higher-dose cohort reinforces the sustained biological activity of SkinJect and supports advancement into the next stage of development. Importantly, we believe this dataset strengthens our position in ongoing and prospective partnering discussions and may accelerate strategic engagement as we evaluate optimal pathways for value creation.” ... Read the full article here. ----- No. 5 MDCX Potential Catalyst - Multiple Technical Indicators Point To This Profile Trending Around Oversold Levels. At 2:00PM EST Tuesday, Barchart was reporting MDCX to have multiple oversold leaning technical indicators. These technicals could be signaling a healthy reversal is approaching in the near term. Here's the definition of a "reversal" from Investopedia: "A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart." Here's the technicals to pay close attention to (as of 2:00PM EST Tuesday): 9-Day Relative Strength Index: 35.60% 14-Day Relative Strength Index: 34.93% When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued. 9-Day Raw Stochastic %D: 14.50% 14-Day Raw Stochastic %D: 14.50% As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued. Keep an eye on these technicals closely. ----- (Nasdaq: MDCX) Recap - These 5 Potential Breakout Catalysts Lead The Way No. 1 - A Low Float Could Create The Environment For Heightened Volatility. No. 2 - A Visibility Boost Is Incoming As MDCX Signs Strategic Media Agreement. No. 3 - An Average Of 6 Analyst Targets Suggest Major Potential Upside (Quadruple-Digit). No. 4 - The Company Reported Positive Topline Data On A Key Phase 2 Study. No. 5 - Multiple Technical Indicators Point To This Profile Trending Around Oversold Levels. ----- Medicus Pharma Ltd. (Nasdaq: MDCX) is on our watchlist as coverage is officially initiated. Updates will be heading your way soon. Keep your eyes peeled. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 04/14/2026 and ending on 04/15/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred forty seven thousand five hundred USD ("Funds"). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/mdcx-7e33i/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice